Boehringer Ingelheim convinces NICE that Pradaxa is cost-effective
This article was originally published in Scrip
Executive Summary
Boehringer Ingelheim has convinced NICE, the health technology appraisal institute for England and Wales, to recommend its blood thinner Pradaxa (dabigatran) for use on the NHS. In August, the institute was undecided about the drug and wanted more information. But final draft guidance published 1 November 2011 says that the drug is a cost-effective alternative to warfarin, the drug that Pradaxa is designed to replace.
You may also be interested in...
German HTA Queries Polivy Benefits Amid Lack Of Evidence
Roche’s lymphoma drug Polivy could face pricing challenges in Germany as it undergoes a full benefit assessment.
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.
New HTA Evidence Guidelines In EU Could Spell Trouble For Advanced Therapy Companies
New guidelines that cast doubt over the use of single-arm and non-randomized studies are “discouraging” for rare disease patients and the advanced therapy sector, says ARM, the Alliance for Regenerative Medicines.